查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553626

转移性肺腺癌治疗市场规模、份额和趋势分析报告：按治疗、最终用途、地区和细分市场预测，2024-2030 年

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment, By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

转移性肺腺癌治疗市场的成长与趋势：

Grand View Research的研究报告显示，到2030年，全球转移性肺腺癌治疗市场规模预计将达到93亿美元，2024年至2030年复合年增长率为11.3%。

有几个重要因素促成了这种扩张，包括患病率上升、治疗技术的进步以及监管和政府支持措施。根据世界卫生组织 (WHO) 的数据，肺癌仍然是全球最常见的癌症，每年约有 250 万新病例，占所有新发癌症病例的 12.4%。这种高盛行率强调了对有效治疗方法的迫切需求。

最近的治疗趋势对市场成长做出了重大贡献。标靶治疗（包括 ALK 抑制剂和 EGFR 抑制剂）等创新彻底改变了转移性肺腺癌的治疗。例如，2024年3月，辉瑞公布了3期CROWN试验的长期追踪资料。本研究评估了第三代 ALK 抑制剂 LORBRENA 与 XALKORI 相比，对新诊断的 ALK 阳性晚期非小细胞肺癌 (NSCLC) 患者的疗效。 Lorbrena（lorlatinib）和Tagrisso（Osimertinib）等药物可以给患者带来新的希望，从而提高生存率和生活品质。此外，查核点抑制剂等免疫疗法的日益普及进一步扩大了治疗选择。

监管机构在促进市场成长方面发挥重要作用。美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等机构对有前景的治疗方法实行了快速核准流程，加快了患者获得新治疗方法的速度。此外，美国国家癌症登月计划和欧盟地平线欧洲计划等政府倡议正在资助研究并支持新型治疗方法的开发，帮助扩大市场并减少转移性肺癌。

转移性肺腺癌治疗市场报告亮点

  • 根据治疗方法，市场分为化疗、标靶治疗、免疫放射线治疗、放射治疗等。 2023年，化疗领域在转移性肺腺癌治疗市场中占最大收益占有率，达33.2%。
  • 2023 年，医院业务占最大收益占有率，达 64.3%。医院通常拥有先进的诊断和治疗设备，使其成为复杂癌症治疗的理想环境。
  • 北美转移性肺腺癌治疗市场是由高疾病发生率和对技术创新的重视所推动的。肺癌，特别是腺癌的盛行率不断增加，导致采用针对肿瘤遗传特征的更个人化的治疗策略。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章转移性肺腺癌治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 转移性肺腺癌治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第 4 章 转移性肺腺癌治疗市场：按治疗分类的估计和趋势分析

  • 转移性肺腺癌治疗的全球市场：按治疗分类的仪表板
  • 转移性肺腺癌治疗的全球市场：治疗变化分析
  • 转移性肺腺癌治疗市场（依治疗、按收益）
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 放射治疗
  • 其他的

第五章转移性肺腺癌治疗市场：按最终用途分类的估计和趋势分析

  • 转移性肺腺癌治疗的全球市场：按最终用途分類的仪表板
  • 转移性肺腺癌治疗的全球市场：最终用途的变化分析
  • 按最终用途分類的收益
  • 医院
  • 专科诊所
  • 其他的

第 6 章 转移性肺腺癌治疗市场：按治疗和最终用途分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2023年主要企业市场占有率分析
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Merck KGaA（EMD Serono）
    • F. Hoffmann-La Roche
    • GSK Plc.
    • AbbVie Inc.
Product Code: GVR-4-68040-431-1

Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends:

The global metastatic lung adenocarcinoma treatment market size is anticipated to reach USD 9.3 billion by 2030, growing at a CAGR of 11.3% from 2024 to 2030, according to a report by Grand View Research, Inc. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

  • Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2023, the chemotherapy segment accounted for the largest revenue share of 33.2% in metastatic lung adenocarcinoma treatment market
  • The hospital segment accounts for the largest revenue share of 64.3% in 2023. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
  • The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. The increasing incidence of lung cancer
      • 3.2.1.2. Advancements in targeted therapies and immunotherapies
      • 3.2.1.3. The growing emphasis on personalized medicine
      • 3.2.1.4. The rising demand for early detection and screening programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatments
      • 3.2.2.2. Limited availability of skilled healthcare professionals
  • 3.3. Metastatic Lung Adenocarcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatments Estimates & Trend Analysis

  • 4.1. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Dashboard
  • 4.2. Global Metastatic Lung Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • 4.3. Global Metastatic Lung Adenocarcinoma Treatment Market by Treatment, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 5.1. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Dashboard
  • 5.2. Global Metastatic Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
  • 5.3. Global Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis by Treatments, and End Use

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company/Competition Categorization
  • 7.2. Vendor Landscape
    • 7.2.1. List of key distributors and channel partners
    • 7.2.2. Key company market share analysis, 2023
    • 7.2.3. Pfizer
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Eli Lilly and Company
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. AstraZeneca
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bristol-Myers Squibb Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Boehringer Ingelheim International GmbH
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Novartis AG
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Merck KGaA (EMD Serono)
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. F. Hoffmann-La Roche
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. GSK Plc.
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. AbbVie Inc.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 North America Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 4 North America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 6 U.S. Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 7 Canada Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 Canada Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 Mexico Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 11 Europe Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 12 Europe Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 13 Europe Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 14 Germany Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 16 UK Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18 France Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 France Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 20 Italy Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 22 Spain Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24 Denmark Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 26 Sweden Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Norway Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 33 China Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 34 China Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 35 Japan Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 Japan Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 India Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 India Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 41 Australia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Thailand Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 45 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 46 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 47 Latin America Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 48 Brazil Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 50 Argentina Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Argentina Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 52 MEA Metastatic Lung Adenocarcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 53 MEA Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 54 MEA Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 55 South Africa Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 56 South Africa Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 UAE Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 UAE Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 61 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Kuwait Metastatic Lung Adenocarcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Metastatic Lung Adenocarcinoma Treatment Market: Market Outlook
  • Fig. 14 Metastatic Lung Adenocarcinoma Treatment Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Metastatic Lung Adenocarcinoma Treatment Market Driver Impact
  • Fig. 18 Metastatic Lung Adenocarcinoma Treatment Market Restraint Impact
  • Fig. 19 Metastatic Lung Adenocarcinoma Treatment Market Strategic Initiatives Analysis
  • Fig. 20 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • Fig. 21 Metastatic Lung Adenocarcinoma Treatment Market: Treatment Outlook And Key Takeaways
  • Fig. 22 Chemotherapy market estimates and forecast, 2018 - 2030
  • Fig. 23 Targeted therapy market estimates and forecast, 2018 - 2030
  • Fig. 24 Immunotherapy market estimates and forecast, 2018 - 2030
  • Fig. 25 Radiation Therapy market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 Metastatic Lung Adenocarcinoma Treatment Market: End Use Movement Analysis
  • Fig. 28 Metastatic Lung Adenocarcinoma Treatment Market: End Use Outlook And Key Takeaways
  • Fig. 29 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 30 Specialty clinics market estimates and forecast, 2018 - 2030
  • Fig. 31 Other market estimates and forecast, 2018 - 2030
  • Fig. 32 Global Metastatic lung adenocarcinoma treatment Market: Regional Movement Analysis
  • Fig. 33 Global Metastatic lung adenocarcinoma treatment Market: Regional Outlook And Key Takeaways
  • Fig. 34 Global Metastatic lung adenocarcinoma treatment market share and leading players
  • Fig. 35 North America, by country
  • Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. key country dynamics
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada key country dynamics
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico key country dynamics
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 UK key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany key country dynamics
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 France key country dynamics
  • Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Italy key country dynamics
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain key country dynamics
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Denmark key country dynamics
  • Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden key country dynamics
  • Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Norway key country dynamics
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 China key country dynamics
  • Fig. 62 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Japan key country dynamics
  • Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 India key country dynamics
  • Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Thailand key country dynamics
  • Fig. 68 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea key country dynamics
  • Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Australia key country dynamics
  • Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil key country dynamics
  • Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina key country dynamics
  • Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa key country dynamics
  • Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia key country dynamics
  • Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 UAE key country dynamics
  • Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait key country dynamics
  • Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Market share of key market players- Metastatic lung adenocarcinoma treatment market